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Abstract
The CONSORT statement recommended that investigators should clearly report which key trial
persons were blinded to treatment allocation and test for the success of blinding. Clinical
researchers, however, more often than not overlook the assessment of the success of blinding. The
severe under-reporting on the success of blinding may improve with awareness of existing
quantitative methods. The two statistical methods, James' blinding index (BI) and Bang's BI, are
currently available. Subjects could be asked to guess their treatment assignment, possibly with an
option to express the degree of certainty. Assessments of blinding at various points may serve
different purposes, i.e. to evaluate comparability between experimental versus control treatments
before the trial by the third party; to examine further comparability and credibility of the control
treatment and patients' expectation about treatment received in early stage of the trial, and to
summarize the overall maintenance of the blinding success at the end of the trial. In this article, we
review BIs and how to use these methods along with discussion of other issues in blinding
assessment and reporting. We contend the two BIs that were independently developed but carry
complementary properties would characterize blinding behaviours in clinical trials qualitatively as
well as quantitatively, and may also shed some lights on the interpretation of the study findings.
Finally we urge the Item 11b of the CONSORT statement to be revised to require the assessment/
reporting of blinding success for all trials that adopt blinding schemes.
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In randomized controlled trials (RCTs), blinding is widely accepted as an important
methodological component to protect internal validity, and significant bias may result from
unsuccessful blinding. Because of the importance of the blinding success, the CONSORT
statement has incorporated this issue as one (Item 11b) of 22 items to be included when
investigators report their RCT (1). However, it is unclear what constitutes adequate evidence
of blinding success.
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Hrobjartsson et al. (2) reported 31 of 1599 medical RCTs (2%) and Fergusson et al. showed
only 7 of 97 (7%) general medicine RCTs and 8 of 94 (8%) psychiatric RCTs; overall only
15 of the 191 (8%) provided evidence on the success of blinding (3). Clearly, a vast majority
of blinded trials do not report test or sufficient evidence for the success of blinding.
Therefore, there is a failure among investigators who undertake clinical trials and journals
that publish the results in reporting the success of blinding. The current highly unsatisfactory
reporting on the success of blinding may be partly due to the lack of appropriate knowledge
or guidance in this field including how to collect data, if there are available methods, what
they are and how to use them. Hence, in this article, we aimed to provide an up-to-date
review of important issues in blinding in RCTs and methods for the assessment and tests for
blinding and to propose a set of guidelines for these tasks.
How to report the success of blinding
Blinding methods
Investigators undertaking clinical trials are recommended to explicitly describe the methods
of blinding they used. Boutron et al. reviewed blinding techniques in pharmacological and
nonpharmacological treatments (4,5). These reviews classified blinding methods that could
help investigators overcome some barriers to successful implementation and maintenance of
blinding.
Who is blinded
It has been recommended that investigators should clearly report which of the following five
categories of key trial persons were blinded to treatment allocation: (i) participants, (ii)
healthcare providers, (iii) data collectors, (iv) outcome assessors (e.g. the data monitoring
board or end-point committee or judicial assessors of outcome) and (v) data analysts (6).
Furthermore, personnel writing the manuscript could be blinded to treatment allocation
(possibly, those writing either of two drafts of a manuscript prior to breaking the
randomization code, with draft 1 written assuming that group A is the treatment group and
draft 2 assuming that group B is the treatment group) (7,8).
Authors frequently use the terms ‘single’, ‘double’ and ‘triple’ blind to describe the blinding
strategy they adopted for their study. Indeed, these terms, particularly ‘double blind’, have
become almost a matter of convention. Devereaux et al. have shown that both physicians
and textbooks vary greatly in their interpretations and definitions of single, double and triple
blinding (9). Haahr and Hrobjartsson also reported that only 2% of articles describing
‘double blind’ trials reported explicitly the blinding status of key trial persons (6). We
believe explicit statements about who were actually blinded (i.e. the blinding status of key
trial persons) should replace the use of current ambiguous or nonspecific terminologies (10).
Who is tested for the success of blinding
Investigators who undertake clinical trials are recommended to clearly report which of the
five categories of key trial persons were tested. We must note that it does not mean that all
key trial persons should be blinded and tested for the success of blinding. The level of
blinding of a trial depends on the nature of the study such as the level of subjectivity of the
outcome and precision needed for the study. However, Hrobjartsson et al. showed that 74%
of trials tested only participants, 13% only data collectors, 10% both participants and data
collectors, and 1% healthcare providers and data collectors (2).
Methods used to assess the success of blinding
Subjects could be asked to guess their treatment assignment, but they may be allowed to
express treatment guess or uncertainty, i.e. subjects' guessing options could be ‘active versus
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placebo (or control) versus do not know’, we call this ‘2 × 3 format’. With successful
blinding, we would expect the number of ‘do not know’ answers to be high or correct and
incorrect guesses to be balanced. An example of this method is the study of Lao et al. (11).
Alternatively, the certainty of the guess could be rated on a 5-point scale (12). For example,
LaRosa et al. asked subjects to rate the extent of certainty about their treatment on the
following scale: 1) strongly believe the treatment is active, 2) somewhat believe the
treatment is active, 3) somewhat believe the treatment is placebo, 4) strongly believe the
treatment is placebo and 5) do not know (13); we call this ‘2 × 5 format’. An optional
ancillary data can be additionally collected from the subjects who initially answered ‘do not
know’ by re-asking them to choose one treatment (in 2×2 format). This datum can be useful
for the purpose of validation of the ‘do not know’ data.
Another method is a pretrial evaluation of the potential for unblinding (14). This procedure
involves conducting a test on an independent panel of volunteers who are not participating
in the actual trial, in a preliminary study by asking them to try to distinguish different
matching preparations for active versus control treatments.
Rees et al. described a fundamentally different method to ascertain the success of blinding
(15). They emphasized that the assessment of belief regarding treatment assignment at a
single cross-sectional session, especially at the end of the trial, does not capture the success
or failure of blinding. This method shifts the focus away from the correctness of beliefs
regarding treatment assignment; instead, it emphasizes the beliefs themselves and their
change pattern during the trial. They concluded that the optimal means of assessing blinding
is an inter-group comparison of the change in beliefs (and not necessarily their correctness)
between the start and end of a trial.
Timing
The optimal timing and frequency of blinding assessments is a controversial issue. Some
researchers believe that end-of-trial tests of blindness might actually be tests of hunches for
efficacy or side effects rather than the success of blinding. This influence can be stronger if
possible side effects have been mentioned as a part of the informed consent procedure (16).
They recommend that the success of blinding should preferably be assessed in the early
stages of the trial before the evidence of efficacy or side effects (17–19). On the other hand,
some researchers recommend end-of-trial (or end of treatment administration if this is more
relevant; for example, when the end point is mortality) tests of blinding. They believe
unblinding can occur at any time during the study and testing at the end is more appropriate
and will not or minimally affect the subject behaviours (20).
On the other hand, as blinding conveys stories during the entire course of the trial, a cross-
sectional assessment will not be able to capture the dynamics of unblinding. Desbiens
recommended the blinding test at several points during the study depending on the duration
of the trial (21). Interestingly, Rees et al. (15) showed that the difference between the six-
point assessment of blinding success during the trial and the two-point model was not
significant. This is important because of concerns that repeated questioning can draw
attention to the issue and may cause additional unblinding and bias.
In conclusion, we recommend assessments of blinding before the trial by the third party for
independent credibility, in the early stage of the trial with great caution for credibility at
specific trial setting, and at the end of the trial for overall assessments of trial participants.
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Descriptive statistics of blinding data can be useful but may not be sufficient and a formal
statistical analysis is encouraged. Hrobjartsson et al. found that 58% of RCTs that claimed
the success of blinding presented no statistical analysis (2). Until now, some traditional
methods such as the chi-squared test or the kappa statistic are often employed.
However, specialized statistical methods for blinding assessment, namely blinding index
(BI), are available these days. James et al. (22) proposed a BI, as a variation of the kappa
coefficient, that is sensitive not to the degree of agreement but to the degree of
disagreement, by placing the highest weight on ‘do not know’ responses. This index ranges
from 0 to 1, 0 being total lack of blinding, 1 being complete blinding and 0.5 being
completely random blinding (i.e. 50% correct and 50% incorrect guesses). If the upper
bound of the confidence interval (CI) of BI is below 0.5 (i.e. CI does not cover the null
value), the study is regarded as lacking blinding. Otherwise, one may conclude that there is
insufficient evidence for unblinding. An example of usage of this method is the study of
Colford et al. (23).
An important assumption in the construction of James' BI is that when a respondent says
that she or he does not know the treatment identity this represents an honest response, not
just a socially desirable response or one that avoids making a judgement. It is therefore
important that investigators encourage the respondents to report their suspicions honestly
when such suspicions exist.
However, in practice, the drug and placebo arms of a clinical trial can exhibit distinct
blinding behaviours not only in magnitude but also in direction. As James' BI is a single
index value that combines blinding data from all arms, it cannot distinguish this difference,
if any, between treatments and can even lead us to a misleading conclusion due to cancelling
out of positive and negative estimates. Moreover, this and other standard methods do not
provide the estimate of the proportion of unblinded participants beyond random chance
level. Investigators may want to know how many participants are unblinded regardless of
the validity and effectiveness of blinding.
Therefore, Bang et al. (24) proposed a new BI to address these issues. Bang's BI can be
directly interpreted as the proportion of the unblinding in each arm and has the ability to
detect different behaviours in different treatment arms including the ‘wishful thinking’
scenario (20). It takes a value between −1 and 1, with 0 as a null value, which indicates the
most desirable situation under random blinding. A positive value may imply failure in
blinding above random guessing (i.e. a majority of participants guess their treatment
allocation correctly), and a negative value may suggest the success of blinding or failure of
blinding in the other direction (i.e. more individuals mistakenly name the alternative
treatment). An example of the usage of this method is the study of Park et al. (25).
Furthermore, the Bang et al. approach allows us to distinguish nine possible blinding
scenarios, determined by the combination of three possible results for each of the two arms
(see Table. 1). The three possible results for each arm are ‘random’ (e.g. indicated by values
of BI sufficiently close to 0), ‘unblinded’ (indicated by BI values significantly larger than 0)
and ‘opposite’ (indicated by BI values significantly lower than 0). Alternatively, these
scenarios can be classified based on a priori chosen (fixed) threshold value for BI (e.g. BI
≶0.2). Clinical investigators may be interested in knowing which category their trials fall
into. Bang et al. emphasized estimation of BI rather than hypothesis testing in evaluating
blinding success due to subjectivity and inherent confounding issues.
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Computing modules for the two BIs are available for Stata (StataCorp LP, College Station,
TX, USA) since March 2008, which are available at
http://ideas.repec.org/c/boc/bocode/s456898.html (20,26).
Reporting of the results
Subjects' answers could be reported for relevant parties of the five categories of key trial
persons who were tested for the success of blinding. Also subjects' answers could be
reported for each trial arms. We recommend investigators report blinding data in 2 × 3 or 2
× 5 tables or adequate details that allow readers to reconstruct one of these tables. Table 3 in
the study of Park et al. (25) is a good example.
Interpretation of the impact of blinding
The author's conclusion about the success of blinding and its ‘potential’ (not definite) effects
or any implications on the study results should be described clearly. Hrobjartsson et al.
showed that the conclusion was unclear or not reported in 32% of RCTs that reported
blinding test results (2).
James' BI could be used to infer the totality of the blinding success in RCTs and hypothesis
testing assuming ‘do not know’ is credible data. Bang's BI could be used to characterize and
evaluate the blinding situation in each trial arm separately, classifying the result into one of
nine qualitative different blinding scenarios, and estimating the percentage of unblinding
beyond chance in each arm.
Most importantly, if significant unblinding occurred, investigators should try to find how
(e.g. physical characteristics such as appearance, taste and smell, therapeutic or side effects,
or accidental disclosure) and when this happened and to make efforts to avoid or minimize
making the same mistakes or misconducts if possible in the current and future trials. For
example, Hertzberg et al. (27) observed frequent unblinding in warfarin arm, compared to
aspirin arm, in two RCTs and provided an explanation that the observed trend may be due to
the number of dose change and haemorrhage, etc. in the warfarin arm.
Examples
Below are three examples of blinding data and tests in scientific research. The first two
examples highlight the use of the 2 × 3 format and the third the use of the 2 × 5 format and
shows usage of ancillary data.
The two other methods, pretrial evaluation of the potential for unblinding (14) and study of
change pattern of beliefs during the trial (15), are not included in these examples. Indeed,
they can provide a significant amount of blinding data. However, it is important to note that
the omission of these methods of blinding assessment are limits to the given research
examples. Ideally, pretrial and posttrial evaluations should be carried out in order to ensure
the blinding, measure any amount of unblinding that took place and generally add to the
scientific knowledge base.
Example 1
An RCT investigated the anti-plaque efficacy of chlorhexidine-containing chewing gum
(28). Placebo was formulated to be identical in size, appearance, taste and package to the
active gum. Study participants, data collector and data analysts were blinded to treatment
allocation. In this study, healthcare providers and outcome assessors were not blinded. To
assess participant blinding, they were asked to guess their treatment assignment (active,
placebo or do not know) on the second day of each test period. The data were originally
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analysed using McNemar's test, yet we re-analysed the results with the two BIs using Stata
10.0 (StataCorp LP) here. Responses of participants are summarized in Table 2. James' BI
was 0.72 (95% CI 0.60–0.84), indicating the success of blinding (P = 0.999). Bang's BI for
active intervention was 0.11 (95% CI −0.17 to 0.39) and for placebo it was 0.05 (95% CI
−0.18 to 0.29), indicating the success of blinding in both active (P = 0.261) and placebo (P
= 0.352) interventions.
Nevertheless, the assessment of blinding in this RCT involves some limitations including: (i)
Pretrial evaluation of the potential for unblinding was not carried out; (ii) Blinding of data
collector and data analysts were not examined; and (iii) End-of-trial tests of blindness were
not conducted and the dynamics of unblinding was unclear.
Example 2
An RCT investigated the analgesic efficacy of acupuncture following surgical removal of
mandibular third molar with partial bony impaction (29). Placebos were sham noninsertion
adjacent to acupuncture points; distal sham shallow insertion at nonpoints and sham shallow
insertion adjacent to acupuncture points; distal sham noninsertion. The surgeon (healthcare
provider), research assistant (data collector), patient and statistician were blinded to group
assignment. However, blindness of outcome assessors was not reported. To assess
participant blinding, they were asked to guess their treatment assignment (acupuncture,
placebo or uncertain) following acupuncture treatment. The blinding data originally were
not analysed and presented as descriptive statistics. Responses of participants are
reconstructed in Table 3. Based on our formal analyses, James' BI was 0.69 (95% CI 0.66–
0.73), indicating the success of blinding (P = 1). Bang's BI for placebo arm was −0.11 (95%
CI −0.19 to −0.02), indicating opposite guessing or successful blinding (P = 0.987). Yet,
Bang's BI for active intervention arm was 0.39 (95% CI 0.29–0.48), indicating tendency to
unblinding (P < 0.001). How to interpret the data? Totality of blinding success in this RCT
may be accepted, yet it showed that subjects in both arms are more likely to report they
received the active treatment. This situation may be classified as the ‘unblinding in active
treatment and opposite guessing in placebo arm’ scenario according to the rule outlined in
Table 1 and we found that this phenomenon is not uncommon in acupuncture studies (25).
Interestingly, the authors reported, although no statistically significant analgesic effect was
observed between the acupuncture and placebo groups, participants in both experiments who
believed they received real acupuncture reported significantly less pain than patients who
believed that they received a placebo. In order to understand this intriguing finding more
objectively, further research should be underway with more blinding data from similar
settings.
Example 3
This example shows the usage of the blinding data in the 2 × 5 format and ancillary data
which can be additionally collected from the subjects who initially answered ‘do not know’.
Data of this example are from a study of cholesterol medication in the elderly (13). At the
end of the trial, participants were asked to rate the extent to which they were certain about
their treatment assignment on the 2 × 5 format (Table 4). Also, subjects who answered ‘do
not know’ were re-asked about their treatment guess one more time (Table 4). Results of
statistical analysis of the primary blinding data are shown in Table 5, with or without
ancillary data. Although conclusions were not changed, the BIs changed as expected when
ancillary data were incorporated, indicating it is possible that, in some RCTs, ancillary data
can be influential, especially when many subjects answered ‘do not know’ initially.
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Implications for future RCTs
As recommended by Boutron et al. (12), we believe that a recommendation on the
appropriate methods to assess the success of blinding should be added to the CONSORT
statement. In accordance with Fergusson et al. (3), we would like to see Item 11b of the
CONSORT statement revised to require the assessment of the blinding success for all
blinded RCTs. Furthermore, the addition of ‘test for blinding success’ to item 9.4.6 of FDA
guideline (please see FDA guidelines at:
http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM129456.pdf) and
section 4 of ADA clinical trial protocols (please see the ADA clinical trials protocols at:
(http://www.ada.org/ada/seal/standards/guide_clinical_trial.pdf) are suggested. Also, we
would like to see the other international regulatory organizations such as The European
Agency for the Evaluation of Medicinal Products (EMEA), Human Subject Protections -
Office of Human Subjects Research, NIH (OHSR), International Committee of Medical
Journal Editors, etc. pay more attention to the blinding issues in RCTs that they sponsor or
publish.
Moreover, researchers are faced with difficulties in identifying RCTs that assessed the
success of blinding in the absence of MeSH terms
(http://www.ncbi.nlm.nih.gov/sites/entrez?db=mesh) or consistent text words in
international electronic databases. Addition of relevant MeSH terms would be a great step in
the dissemination and generalization of assessment of blinding success. Finally, as
recommended by Desbiense (30), we believe a test for blinding success should become a
standard feature of RCTs whenever blinding is implemented in a trial in order to be
designated a ‘well-designed and well-conducted trial’. Investigators undertaking clinical
trials, protocol reviewers and journal editors should make a concerted effort to incorporate,
report and publish such information for good clinical research practice and eventually to
understand its potential impacts on study results (i.e. treatment effectiveness/efficacy).
Conclusion
In conclusion, we suggest a set of guidelines for researchers in clinical trials.
• Clearly report methods of blinding.
• Clearly report which of the five categories of key trial persons were blinded to
treatment allocation and tested for the success of blinding.
• Conduct a pretrial evaluation of the potential for unblinding by the third party.
• Ask subjects to guess their treatment assignment using three or five choices for
response in early stage of the trial with great caution, and at the end of the trial.
• Report the subjects' answers for relevant parties of the five categories of key trial
persons who were tested. Also report the subjects' answers for each trial arms. We
recommend blinding data be presented in 2 × 3 or 2 × 5 tables.
• Analyse the data using James' (22) and Bang's (24) BIs.
• Carefully interpret the impact of blinding and its potential effects on the study
results, if possible. One may use James' BI to conclude the totality of the blinding
success of the RCT and hypothesis testing and use the Bang's BI to conclude the
blinding situation in each trial arm, classifying the result into one of nine blinding
scenarios, and to estimate the percentage of unblinding beyond chance in each arm.
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• If significant unblinding occurred, try to find out how (e.g. physical characteristics
such as appearance, taste and smell, therapeutic or side effects, or accidental
disclosure) and when this happened.
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Table 1
Nine different blinding scenarios and their frequencies as reported in the Park et al.
literature review (20)
Active group Placebo group Frequencies, n (%) 95% Confidence interval (%)b
Random guess Random guess 10 (15.9) 8–27
Random guess Opposite guessa 2 (2.3) 0.5–11
Random guess Unblinded 5 (7.9) 2–18
Unblinded Unblinded 18 (28.6) 18–41
Unblinded Opposite guessa 11 (17.5) 9–29
Unblinded Random guess 15 (23.8) 14–36
Opposite guess Guessa 1 (1.6) 0.08–9
Opposite guess Random guess 0 (0) 0–7
Opposite guess Unblinded 1 (1.6) 0.08–9
Total 63 (100) 92–100
Random guess: −0.2 < BI < 0.2; unblinded: BI >0.2; opposite guess: BI <−0.2.
a
Wishful thinking, RCT participants tend to think they are allocated to the active group even if not in reality.
b
The confidence intervals were calculated with a correction for continuity.
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Table 5
Results of data analysisa of Table 4
Methods Index P-value 95% Confidence interval Conclusion
James 0.74 1 0.71–0.78 Blinded
Bang – Drug/2 × 5 0.16 <0.001 0.12–0.20 Unblinded
Bang – Drug/2 × 5b 0.15 <0.001 0.11–0.20 Unblinded
Bang – Placebo/2 × 5 −0.00 0.53 −0.06 to 0.05 Blinded
Bang – Placebo/2 × 5b 0.01 0.38 −0.05 to 0.08 Blinded
a
STATA commands used were (the ‘ ’ symbol indicates push of Enter key):
matrix define A = (38,44,21,4,170\11,16,21,8,83)  blinding A 
matrix define B = (79,86,5\36,45,2)  blinding A, ancillary (B) .
b
Showed results with incorporation of ancillary data for ‘Do not know’ responses.
Community Dent Oral Epidemiol. Author manuscript; available in PMC 2011 February 23.
